It seems my industry colleagues have been wrongly optimistic and also hyper cynical. At least that is the bottom line of the read I get in comparing the analysis of the 2nd annual Semaphore Confidence Survey with last year’s results. And some people have very...
The Valley of Death for a Life Sciences company is that space, as coined by the NCI’s Director of Small Business Innovation Research Programs Michael Weingarten, between a Phase 2 SBIR grant and the commercial success of the technology that is being funded and...
So what’s wrong with Biotech financing today? What will it take to bring the Biotech market out of the doldrums and back into action? If you are having trouble finding financing for your next greatest idea then the only comforting news is that you are not alone....
Blog Series: 1 of 4 When it comes to venture capital and growth equity investments, the bottom line is the top line. If a company can grow its revenue, then odds are it will generate a strong return for its investors. Market due diligence is a key component of...
I live in Massachusetts and let’s face it; we live in what is perceived to be a high tax state. Whether this belief is true or not we share that belief of high taxes with California, New York, New Jersey and Michigan. On the other hand Florida, Texas and North...
I think I was subscriber number 293 – certainly somewhere under one thousand. That got me the privilege of sharing a Dim Sum meal in Boston’s Chinatown with the curly haired, lightening talking, quick-fire questioning editor of what was then known as PE Week Wire. In...
